HIMS vs. NTRA, FMS, GH, OPCH, RDNT, BTSG, SHC, SGRY, PRVA, and CON
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Fresenius Medical Care (FMS), Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), and Concentra Group Holdings Parent (CON). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs. Its Competitors
Natera (NASDAQ:NTRA) and Hims & Hers Health (NYSE:HIMS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
In the previous week, Hims & Hers Health had 16 more articles in the media than Natera. MarketBeat recorded 33 mentions for Hims & Hers Health and 17 mentions for Natera. Natera's average media sentiment score of 1.50 beat Hims & Hers Health's score of 0.66 indicating that Natera is being referred to more favorably in the media.
Natera has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
Natera received 448 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 68.90% of users gave Natera an outperform vote while only 35.11% of users gave Hims & Hers Health an outperform vote.
99.9% of Natera shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 7.6% of Natera shares are owned by insiders. Comparatively, 13.7% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Hims & Hers Health has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of 8.19% compared to Natera's net margin of -14.01%. Hims & Hers Health's return on equity of 10.97% beat Natera's return on equity.
Natera currently has a consensus target price of $184.63, suggesting a potential upside of 12.34%. Hims & Hers Health has a consensus target price of $38.00, suggesting a potential downside of 33.20%. Given Natera's stronger consensus rating and higher possible upside, research analysts plainly believe Natera is more favorable than Hims & Hers Health.
Summary
Natera and Hims & Hers Health tied by winning 9 of the 18 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy HIMS Stock Free HIMS Stock Alerts